A Study of Ruxolitinib vs Best Available Therapy (BAT) in Patients With Steroid-refractory Chronic Graft vs. Host Disease (GvHD) After Bone Marrow Transplantation (REACH3)
Incyte Corporation
Incyte Corporation
Medical College of Wisconsin
Case Comprehensive Cancer Center
Medical College of Wisconsin
Fred Hutchinson Cancer Center
Dana-Farber Cancer Institute
Fred Hutchinson Cancer Center
The Affiliated Hospital of the Chinese Academy of Military Medical Sciences
FDA Office of Orphan Products Development
Fred Hutchinson Cancer Center
Hoffmann-La Roche